PDF(Pubmed)
Abstract：
BACKGROUND: The study aims to explore the clinical effects of Vitamin D (VitD) supplements for Hashimoto\'s Thyroiditis (HT), which are unclear according to other studies.
METHODS: Female patients with newly diagnosed HT from January to June in 2018 were included. This study is registered in the Chinese Clinical Trials Registry with registration number ChiCTR1800014619 (URL: https://www.chictr.org.cn/). Patients were randomly assigned to the treatment group and the control group. The treated group were further randomly assigned to a VitD supplement group or VitD & Levothyroxine (L-T4) supplement group. After 6 months, we recorded and compared various indicators between different groups.
RESULTS: A total of 179 patients, aged 12 to 75, were used for statistical analysis. A significant decrease in Thyroid Peroxidase Antibody (TPOAb) level was observed (351.70±183.25 vs. 246.37±157.39, P<0.001) in the VitD-treated group compared to the control group after 6 months. Free Triiodothyronine (FT3) and Free Thyroxine (FT4) level were increased (FT3: 4.30±0.64 vs. 4.84±0.9, P<0.001; FT4: 15.15±1.93 vs. 17.38±2.97, P<0.001), and Thyroid-Stimulating Hormone (THS) level was decreased (3.58±1.78 vs. 2.25±1.22, P<0.001) in the VitD-treated group compared to the control group.
CONCLUSIONS: VitD supplementation can effectively slow progression of hypothyroidism, improve thyroid function, and reduce the anti-thyroid antibody level. This suggests it is useful for HT.
METHODS: Female patients with newly diagnosed HT from January to June in 2018 were included. This study is registered in the Chinese Clinical Trials Registry with registration number ChiCTR1800014619 (URL: https://www.chictr.org.cn/). Patients were randomly assigned to the treatment group and the control group. The treated group were further randomly assigned to a VitD supplement group or VitD & Levothyroxine (L-T4) supplement group. After 6 months, we recorded and compared various indicators between different groups.
RESULTS: A total of 179 patients, aged 12 to 75, were used for statistical analysis. A significant decrease in Thyroid Peroxidase Antibody (TPOAb) level was observed (351.70±183.25 vs. 246.37±157.39, P<0.001) in the VitD-treated group compared to the control group after 6 months. Free Triiodothyronine (FT3) and Free Thyroxine (FT4) level were increased (FT3: 4.30±0.64 vs. 4.84±0.9, P<0.001; FT4: 15.15±1.93 vs. 17.38±2.97, P<0.001), and Thyroid-Stimulating Hormone (THS) level was decreased (3.58±1.78 vs. 2.25±1.22, P<0.001) in the VitD-treated group compared to the control group.
CONCLUSIONS: VitD supplementation can effectively slow progression of hypothyroidism, improve thyroid function, and reduce the anti-thyroid antibody level. This suggests it is useful for HT.
摘要：
背景：该研究旨在探讨维生素D（VitD）补充剂对桥本甲状腺炎（HT）的临床效果，根据其他研究还不清楚。
方法：纳入2018年1-6月女性初诊HT患者。本研究在中国临床试验注册中心注册，注册号为ChiCTR1800014619（网址：https://www。chictr.org.cn/)。将患者随机分为治疗组和对照组。将治疗组进一步随机分配到VitD补充组或VitD&左甲状腺素(L-T4)补充组。六个月后,我们记录并比较了不同组间的各项指标.
结果：总共179名患者，年龄在12至75岁之间，用于统计分析。甲状腺过氧化物酶抗体（TPOAb）水平显着下降（351.70±183.25vs.与对照组相比，VitD治疗组6个月后246.37±157.39，P<0.001）。游离三碘甲状腺原氨酸（FT3）和游离甲状腺素（FT4）水平升高（FT3：4.30±0.64vs.4.84±0.9，P<0.001；FT4：15.15±1.93vs.17.38±2.97,P<0.001),促甲状腺激素（THS）水平降低（3.58±1.78vs.与对照组相比，VitD治疗组的2.25±1.22，P<0.001）。
结论：补充VitD可有效减缓甲状腺功能减退症的进展，改善甲状腺功能，并降低抗甲状腺抗体水平。这表明它对于HT是有用的。
方法：纳入2018年1-6月女性初诊HT患者。本研究在中国临床试验注册中心注册，注册号为ChiCTR1800014619（网址：https://www。chictr.org.cn/)。将患者随机分为治疗组和对照组。将治疗组进一步随机分配到VitD补充组或VitD&左甲状腺素(L-T4)补充组。六个月后,我们记录并比较了不同组间的各项指标.
结果：总共179名患者，年龄在12至75岁之间，用于统计分析。甲状腺过氧化物酶抗体（TPOAb）水平显着下降（351.70±183.25vs.与对照组相比，VitD治疗组6个月后246.37±157.39，P<0.001）。游离三碘甲状腺原氨酸（FT3）和游离甲状腺素（FT4）水平升高（FT3：4.30±0.64vs.4.84±0.9，P<0.001；FT4：15.15±1.93vs.17.38±2.97,P<0.001),促甲状腺激素（THS）水平降低（3.58±1.78vs.与对照组相比，VitD治疗组的2.25±1.22，P<0.001）。
结论：补充VitD可有效减缓甲状腺功能减退症的进展，改善甲状腺功能，并降低抗甲状腺抗体水平。这表明它对于HT是有用的。
